



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 13 2003

TECH CENTER 1600/2900

In re application of:

Springer *et al.*

Appl. No.: 09/826,210

Filed: April 5, 2001

For: **Analogs of Human basic Fibroblast
Growth Factor**

Confirmation No.: 8485

Art Unit: 1647

Examiner: Saoud, C. J.

Atty Docket: 1503.0220003/JAG/THN

**Amendment and Reply Under 37 C.F.R § 1.111 and
Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a)**

Commissioner for Patents
Washington, DC 20231

Sir:

In reply to the Office Action dated September 11, 2002 (PTO File Wrapper Paper No. 7), Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.111 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper.

However, if additional extensions of time are necessary to prevent abandonment of this